Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, Cytokinetics to Build Joint Compound Library

SAN FRANCISCO, Jan. 3 - Exelixis and Cytokinetics will partner in building a small molecule compound library, the companies said on Thursday.


The South San Francisco-based companies will jointly own and have the right to use in internal drug discovery any compounds generated as a result of the collaboration, the companies said. While both companies will design small molecules, Exelixis will be responsible for synthesizing compounds using its combinatorial chemistry platforms. Exelixis will receive cash payments for creating the compounds.


Financial details of the deal were not disclosed.


Cytokinetics is working to develop medical therapies based on a cell's cytoskeleton.


"In a very short period of time, Exelixis has built a robust chemistry program that is an asset for generating novel, high quality compounds to advance our internal discovery efforts and for corporate partnering," George Scangos, CEO of Exelixis, said in a statement. "The compounds generated through this collaboration have the potential to benefit both companies' pipelines."


In Oct., Exelixis entered a deal with Sunnyvale, Calif.-based Scios to jointly develop a compound library.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.